JM 010

Drug Profile

JM 010

Alternative Names: AV-2860; JM-010

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Contera Pharma
  • Developer Bukwang Pharmaceutical; Contera Pharma
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Dopamine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Drug-induced dyskinesia

Most Recent Events

  • 03 Aug 2017 JM 010 is still in phase II clinical development for Drug-induced dyskinesia in South Africa (Contera Pharma website, August 2017)
  • 01 Jan 2016 Contera Pharma completes a phase II trial in Drug-induced dyskinesia in South Africa (NCT02439203)
  • 01 May 2015 Phase-II clinical trials in Drug-induced dyskinesia in South Africa (unspecified route) (NCT02439203)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top